Sign in to view content

Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial

Diana V Do, MD, FASRS

Video
Published 2024

Related

Progression of diabetic retinopathy in patients treated with 0.2 μg/day
Raymond Iezzi, MD, MS
Updates from the Field
2017
Episode 143: Journal Club, Pediatric Retinal Detachment Surgery, Open Label Extension RISE and RIDE, BP Changes during Injections
Jayanth Sridhar, MD
Member Podcasts
2018
Prospective Evaluation of Pain and Inflammation Following Injection of Aflibercept or Ranibizumab in Patients With Diabetic Macular Edema: SOLAR Study
Nikolas JS London, MD, FACS, FASRS
Annual Meeting Talks
2018

Category: Retinal Vascular Disease

See more